In this blog, we explore three key actions linked to strategic purchasing that India’s AB-PMJAY scheme can apply by leveraging its influence as a major purchaser of services and goods in the country. These same actions are readily generalizable and can replicated by other jurisdictions to save money, improve health and accelerate a country’s journey towards UHC.
CGD Policy Blogs
In January 2021, India embarked on one of the world’s largest vaccination drives ever in an attempt to control COVID-19 in the country. After nine months, 29 percent of the national population is partially vaccinated, and only 15 percent is fully vaccinated.
Vaccines have become a central instrument of our long-term response to the pandemic. Vaccination campaigns have now started around the world and will confer significant direct protection against infection, severe illness, and death to those inoculated. It may also protect against transmission, though robust evidence is yet to be confirmed.
More than Oxygen Supply: How to Make the Current Global Fund COVID-19 Response Mechanism a Success for Patients
The global COVID-19 pandemic has highlighted the pressing need to improve oxygen supplies around the world. In this blog, we highlight key objectives that countries need to consider in their funding applications for support from the CRM for the successful scale up of oxygen and critical care.
India’s second COVID-19 wave has been explosive, reaching world record totals of over 300,000 daily officially reported cases. The true number is likely to be much higher, with a large number of cases missed as indicated by the delays in testing and rapidly rising positivity rates - currently one in every four people tested are positive for COVID-19 across India. Leading models estimate that there could be over 1 million cases per day. The health service has collapsed, with queues of ambulances parked outside full hospitals, oxygen and drug shortages in multiple states, and life-saving non-COVID services interrupted.
Rapid Priority Setting in Low- and Middle-Income Countries: The Potential of Adaptive Health Technology Assessments
Health budgets are limited and decision makers in all countries face very challenging decisions about which health interventions will be provided, and which will not. COVID has only added to this pressing priority setting problem. In this blog, we highlight key takeaways from our recent commentary in the BMJ Global Health, where we make the case for “adaptive health technology assessment,” or “aHTA.”
In 2020, epidemiological modelling went from relative obscurity to being central in helping governments, and the public, understand COVID-19 as it spread around the world. In 2021, with the emergence of effective COVID-19 vaccines, Health Technology Assessment (HTA) will be critical to making the best possible decisions in bringing the pandemic under control, particularly in low-and middle-income countries (LMICs). In this blog we look at the potential of HTA to inform how much vaccine countries should buy, who should pay, and how vaccines can be most effectively delivered.
With a population of 1.4 billion and very limited public funding for healthcare, how can the government of India ensure cost-effectiveness across their health scheme?
The authors look at the feasibility of the drug dexamethasone in low-income countries.